| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-500SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF950-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB9028-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-51582SS | |||
| Azide and BSA Free | NBP2-80720 | |||
![Western Blot: eNOS Antibody - BSA Free [NB300-500] - Fractionated, compared to single exposure, radiation more profoundly suppressed TM and eNOS. Representative Western blot analysis and quantification of KLF2 (n = 5) and KLF4 (n = 3) levels in whole-cell lysates from nonirradiated (sham) and irradiated HUVECs 4 h and 24 h after exposure to either five fractions of 2 Gy (5 x 2 Gy) or single exposure to 10 Gy. Fractions delivered at 24-h intervals. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32382091/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/eNOS Antibody - BSA Free-Western Blot-NB300-500-img0007.jpg "<b>Biological Strategies Validation. </b>Western Blot: eNOS Antibody - BSA Free [NB300-500] - Fractionated, compared to single exposure, radiation more profoundly suppressed TM and eNOS. Representative Western blot analysis and quantification of KLF2 (n = 5) and KLF4 (n = 3) levels in whole-cell lysates from nonirradiated (sham) and irradiated HUVECs 4 h and 24 h after exposure to either five fractions of 2 Gy (5 x 2 Gy) or single exposure to 10 Gy. Fractions delivered at 24-h intervals. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32382091/) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: eNOS Antibody - BSA Free [NB300-500] - Expression of endothelial markers indicate functional endothelium in TEVG. Whole mount staining of native aorta and TEVG. VE-cadherin is a marker of cellular borders of endothelial cells (green). Endothelial nitric oxide synthase (eNOS) is a marker of a functional endothelium (red). DAPI is a nuclear stain (blue). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0120328), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/eNOS-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NB300-500-img0006.jpg)
![Immunohistochemistry-Paraffin: eNOS Antibody - BSA Free [NB300-500] - Staining of eNOS in human lung tissue.](http://images.novusbio.com/fullsize/eNOS-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NB300-500-img0003.jpg)
![Immunohistochemistry-Paraffin: eNOS Antibody - BSA Free [NB300-500] - Mouse Carotid Artery stained with eNOS antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/eNOS-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NB300-500-img0004.jpg)
![Immunohistochemistry: eNOS Antibody - BSA Free [NB300-500] - Staining of representative pulmonary artery endothelial cells from rats subjected to CON=Control Group, ALI=Acute lung injury Group, LV=Low tidal volume Group, VLV=Very low tidal volume Group, MV=Large tidal volume Group. Dark brown staining of indicates eNOS-positive cells. Magnification x400.](http://images.novusbio.com/fullsize/eNOS-Antibody---BSA-Free-Immunohistochemistry-NB300-500-img0005.jpg)
![Western Blot: eNOS Antibody - BSA Free [NB300-500] - Mevalonate pathway inhibitors reversed fractionated-radiation–induced suppression of KLF2 & its downstream target molecules. Representative Western blot analysis & quantification of KLF2, TM, & eNOS 4 h after exposure to five fractions of 2 Gy (a) in presence or absence of atorvastatin (1 μM) or GT3 (5 μM) & (b) in presence or absence of GGTi (10 μM) (n = 3). beta -actin served as a loading control. (n, number of independent experiments performed; a, significant statistical difference between nonirradiated & irradiated groups; b, significant statistical difference between fractionated irradiation & single exposure; *, p < 0.05; **, p < 0.01; ***, p < 0.001). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32382091), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-500_rabbit-polyclonal-enos-antibody-31020241534534.jpg)
![Western Blot: eNOS Antibody - BSA Free [NB300-500] - Upregulation of HMG-CoA reductase in shPLD2 cells decreases eNOS expression. (A) Representative western blot of HMG-CoA reductase in Scramble & shPLD2 cells. The regions of the Western blots containing the HMG-CoA reductase & actin immunoreactive bands were scanned & the relative abundance of the individual samples quantified using an Odyssey CLx imaging system (B) Quantification of western blots with HMG-CoA reductase normalized to actin (n = 4 experiments). (C) N-SIM microscopy of HMG-CoA reductase; Bar, 7.5 μM. (D) RT-PCR of HMG-CoA reductase in Scramble & shPLD2 cells (n = 3). (E) Western blot of eNOS after treatment with NFOT & Simvastatin. Representative image of 3 experiments. The regions of the Western blots (Suppl. Figure 2) containing the eNOS & actin immunoreactive bands were scanned & the relative abundance of the individual samples quantified using an Odyssey CLx imaging system. (F) Quantification of western blots with eNOS levels normalized to actin (n = 3). Comparisons without bars made to untreated Scramble values. (G) eNOS activity after treatment with Simvastatin (n = 7). Mean ± SEM; *p < 0.05; **p < 0.01; ***p ≤ 0.001; One-way ANOVA with Bonferroni’s Multiple Comparison Test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28831159), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-500_rabbit-polyclonal-enos-antibody-310202416212339.jpg)
![Western Blot: eNOS Antibody - BSA Free [NB300-500] - The human PLD2 polymorphism R172C does not alter eNOS signaling but does decrease caveolin-1 protein levels. Overexpression of HA-tagged hPLD2 (A) & HA-R172C-PLD2 (B) in HeLa cells, visualized using anti-HA immunofluorescent staining (green). Arrowhead, PLD2 localization in filopodia; chevron, in peripheral actin ruffles; *, in dorsal actin ruffles; arrow, in subcortical actin network. Bar, 7.5 μM. Representative image of multiple experiments. (C) Representative western blot of eNOS after transfection of HA-hPLD2 or HA-R172C-PLD2 into shPLD2 cells. The regions of the Western blots containing the eNOS & actin immunoreactive bands were scanned & the relative abundance of the individual samples quantified using an Odyssey CLx imaging system. (D) Quantification of western blotting with eNOS levels normalized to actin (n = 3). (E) eNOS activity as measured by nitrate formation (n = 7). Lane 1 vs 2, P = 0.0021; lane 2 vs 3, P = 0.00035; lane 2 vs 4, P = 0.00012. (F–I) N-SIM microscopy of plasma membrane eNOS & caveolin-1. Bar, 7.5 μM. Representative image of multiple Scramble or shPLD2 cells imaged. Cells in H & I were selected for imaging based on expression of HA-hPLD2 or HA-R172C-PLD2 as visualized by anti-HA immunofluorescence in a separate channel (not shown). Mean ± SEM; *p < 0.05; **p < 0.01; ***p ≤ 0.001; One-way ANOVA with Bonferroni’s Multiple Comparison Test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28831159), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-500_rabbit-polyclonal-enos-antibody-310202416212351.jpg)
![Western Blot: eNOS Antibody (6H2) [NBP1-51582] - Western blot analysis of HUVEC cells (A) using eNOS antibody at a concentration of 2 ug/ml.](http://images.novusbio.com/fullsize/eNOS-Antibody-6H2-Western-Blot-NBP1-51582-img0003.jpg "Western Blot: eNOS Antibody (6H2) [NBP1-51582] - Western blot analysis of HUVEC cells (A) using eNOS antibody at a concentration of 2 ug/ml.")
![Immunohistochemistry-Paraffin: eNOS Antibody (6H2) [NBP1-51582] - IHC staining of eNOS in human placenta using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/eNOS-Antibody-6H2-Immunohistochemistry-Paraffin-NBP1-51582-img0004.jpg)
![Immunohistochemistry-Paraffin: eNOS Antibody (6H2) [NBP1-51582] - Immunohistochemical analysis of paraffin-embedded human lymph node (left) and colon cancer (right) tissues using eNOS mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/eNOS-Antibody-6H2-Immunohistochemistry-Paraffin-NBP1-51582-img0001.jpg)
![Immunohistochemistry-Paraffin: eNOS Antibody (6H2) [NBP1-51582] - Immunohistochemical analysis of paraffin-embedded human stomach cancer (left) and ovary cancer (right) tissues using eNOS mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/eNOS-Antibody-6H2-Immunohistochemistry-Paraffin-NBP1-51582-img0002.jpg)
![N/A eNOS [Biotin]](http://images.novusbio.com/fullsize2/DATA_eNOS_DY95005_ELISA_2566.jpg "N/A eNOS [Biotin]")
![Western Blot: eNOS [p Ser1177] Antibody [NBP3-05432] - Analysis of extracts of NIH/3T3 cells, using eNOS antibody (NBP3-05432) at 1:1000 dilution. NIH/3T3 cells were treated by EGF (100ng/mL) for 30 minutes after serum-starvation overnight. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% BSA. Detection: ECL Enhanced Kit. Exposure time: 60s.](http://images.novusbio.com/fullsize/eNOS-[p-Ser1177]-Antibody-Western-Blot-NBP3-05432-img0004.jpg "Western Blot: eNOS [p Ser1177] Antibody [NBP3-05432] - Analysis of extracts of NIH/3T3 cells, using eNOS antibody (NBP3-05432) at 1:1000 dilution. NIH/3T3 cells were treated by EGF (100ng/mL) for 30 minutes after serum-starvation overnight. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% BSA. Detection: ECL Enhanced Kit. Exposure time: 60s.")
![Immunohistochemistry-Paraffin: eNOS [p Ser1177] Antibody [NBP3-05432] - Mouse pancreas using eNOS [p Ser1177] antibody (NBP3-05432) at dilution of 1:200 (40x lens).](http://images.novusbio.com/fullsize/eNOS-[p-Ser1177]-Antibody-Immunohistochemistry-Paraffin-NBP3-05432-img0002.jpg)
![Western Blot: eNOS [p Ser1177] Antibody [NBP3-05432] - Analysis of extracts of SKOV3 cells, using eNOS antibody (NBP3-05432). SKOV3 cells were treated by EGF. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% BSA.](http://images.novusbio.com/fullsize/eNOS-[p-Ser1177]-Antibody-Western-Blot-NBP3-05432-img0003.jpg)
![Immunohistochemistry-Paraffin: eNOS [p Ser1177] Antibody [NBP3-05432] - Mouse spinal cord using eNOS [p Ser1177] antibody (NBP3-05432) at dilution of 1:200 (40x lens).](http://images.novusbio.com/fullsize/eNOS-[p-Ser1177]-Antibody-Immunohistochemistry-Paraffin-NBP3-05432-img0001.jpg)
![Western Blot: eNOS Antibody (M221) [NBP3-23209] - Western blot analysis of human umbilical vein endothelial cells before (lanes 1, 3, 5) and after (lanes 2, 4, 6) treatment with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).](http://images.novusbio.com/fullsize/nbp3-23209_mouse-enos-mab-m221-19920231856919.jpg "Western Blot: eNOS Antibody (M221) [NBP3-23209] - Western blot analysis of human umbilical vein endothelial cells before (lanes 1, 3, 5) and after (lanes 2, 4, 6) treatment with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).")
![Immunocytochemistry/Immunofluorescence: eNOS Antibody (M221) [NBP3-23209] - Immunocytochemical labeling of endothelial nitric oxide synthase (eNOS) in paraformaldehyde-fixed and NP-40-permeabilized human umbilical vein endothelial cells. The cells were labeled with mouse monoclonal eNOS (NBP3-23209) and rabbit polyclonal eNOS (NBP3-23210) antibodies, then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.](http://images.novusbio.com/fullsize/nbp3-23209_mouse-enos-mab-m221-11920231633165.jpg)
![Immunocytochemistry/Immunofluorescence: eNOS Antibody [NBP3-23210] - Immunocytochemical labeling of endothelial nitric oxide synthase (eNOS) in paraformaldehyde-fixed and NP-40-permeabilized human umbilical vein endothelial cells. The cells were labeled with mouse monoclonal eNOS (NBP3-23209) and rabbit polyclonal eNOS (NBP3-23210) antibodies, then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.](http://images.novusbio.com/fullsize/nbp3-23210_rabbit-enos-pab-1992023141014.jpg "Immunocytochemistry/Immunofluorescence: eNOS Antibody [NBP3-23210] - Immunocytochemical labeling of endothelial nitric oxide synthase (eNOS) in paraformaldehyde-fixed and NP-40-permeabilized human umbilical vein endothelial cells. The cells were labeled with mouse monoclonal eNOS (NBP3-23209) and rabbit polyclonal eNOS (NBP3-23210) antibodies, then the antibodies were detected using appropriate secondary antibodies conjugated to Cy3.")
![Western Blot: eNOS Antibody [NBP3-23210] - Western blot analysis of human umbilical vein endothelial cells before (lanes 1, 3, 5) and after (lanes 2, 4, 6) treatment with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).](http://images.novusbio.com/fullsize/nbp3-23210_rabbit-enos-pab-19920231856933.jpg)
![Western Blot: eNOS [p Tyr657] Antibody [NBP3-23185] - Western blot analysis of human umbilical vein endothelial cells stimulated with pervanadate (1 mM) for 30 min. (lanes 1, 3, & 5) then the blot was treated with alkaline phosphatase (lanes 2, 4, & 6). The blots were probed with anti-eNOS monoclonal antibody (NBP3-23209; lanes 1 & 2), anti-eNOS (Tyr-657) phospho-specific antibody (NP4031; lanes 3 & 4), or anti-eNOS polyclonal antibody (NBP3-23210; lanes 5 & 6).](http://images.novusbio.com/fullsize/nbp3-23185_rabbit-enos-p-tyr657-pab-119202316331612.jpg "Western Blot: eNOS [p Tyr657] Antibody [NBP3-23185] - Western blot analysis of human umbilical vein endothelial cells stimulated with pervanadate (1 mM) for 30 min. (lanes 1, 3, & 5) then the blot was treated with alkaline phosphatase (lanes 2, 4, & 6). The blots were probed with anti-eNOS monoclonal antibody (NBP3-23209; lanes 1 & 2), anti-eNOS (Tyr-657) phospho-specific antibody (NP4031; lanes 3 & 4), or anti-eNOS polyclonal antibody (NBP3-23210; lanes 5 & 6).")
![Immunocytochemistry/Immunofluorescence: eNOS [p Tyr657] Antibody [NBP3-23185] - Immunocytochemical labeling of nNOS phosphorylation in rat PC12 cells differentiated with NGF. The cells were probed with mouse monoclonal (mAb) nNOS (NBP3-23224), and rabbit polyclonal (pAb) nNOS (C-terminal region), nNOS (Tyr-895)/eNOS (Tyr-657), and nNOS (Tyr-1326)/iNOS (Tyr-1055). The antibodies were detected using appropriate secondary antibody conjugated to DyLight(R) 594.](http://images.novusbio.com/fullsize/nbp3-23185_rabbit-enos-p-tyr657-pab-19920231410130.jpg)
![Western Blot: eNOS Overexpression Lysate (Adult Normal) [NBP2-10685] Left-Empty vector transfected control cell lysate (HEK293 cell lysate); Right -Over-expression Lysate for eNOS.](http://images.novusbio.com/fullsize/eNOS-Overexpression-Lysate-Adult-Normal-Western-Blot-NBP2-10685-img0002.jpg "Western Blot: eNOS Overexpression Lysate (Adult Normal) [NBP2-10685] Left-Empty vector transfected control cell lysate (HEK293 cell lysate); Right -Over-expression Lysate for eNOS.")
![Western Blot: eNOS [p Ser632] Antibody (M232) [NBP3-23181] - Western blot analysis of human umbilical vein endothelial cells stimulated with Calyculin A and untreated (lanes 1, 3, 5) or treated (lanes 2, 4, 6) with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).](http://images.novusbio.com/fullsize/nbp3-23181_mouse-enos-p-ser632-mab-m232-11920231665313.jpg "Western Blot: eNOS [p Ser632] Antibody (M232) [NBP3-23181] - Western blot analysis of human umbilical vein endothelial cells stimulated with Calyculin A and untreated (lanes 1, 3, 5) or treated (lanes 2, 4, 6) with lambda phosphatase. The blots were probed with anti-endothelial Nitric Oxide Synthase (eNOS) monoclonal antibody (lanes 1 & 2), anti-eNOS (Ser-632) phospho-specific antibody (lanes 3 & 4), and anti-eNOS polyclonal antibody (lanes 5 & 6).")
![Western Blot: eNOS Antibody [NBP3-23180] - Western blot analysis of human umbilical vein endothelial cells treated with calyculin A (100 nM) for 30 min. (lanes 1, 3, 5 & 7) then the blots were treated with lambda phosphatase (lanes 2, 4, 6 & 8). The blots were probed with anti-endothelial nitric oxide synthase (eNOS) (C-terminal region) (lanes 1 & 2), anti-eNOS (Ser-632) (lanes 3 & 4), anti-eNOS (Ser-1177) (lanes 5 & 6) and anti-eNOS (a.a. 1172-1181) (lanes 7 & 8).](http://images.novusbio.com/fullsize/nbp3-23180_rabbit-enos-pab-19920231759442.jpg "Western Blot: eNOS Antibody [NBP3-23180] - Western blot analysis of human umbilical vein endothelial cells treated with calyculin A (100 nM) for 30 min. (lanes 1, 3, 5 & 7) then the blots were treated with lambda phosphatase (lanes 2, 4, 6 & 8). The blots were probed with anti-endothelial nitric oxide synthase (eNOS) (C-terminal region) (lanes 1 & 2), anti-eNOS (Ser-632) (lanes 3 & 4), anti-eNOS (Ser-1177) (lanes 5 & 6) and anti-eNOS (a.a. 1172-1181) (lanes 7 & 8).")